Young blood transfusion: Difference between revisions

Browse history interactively ← Previous edit Next edit →Content deleted Content addedVisual WikitextInline

Revision as of 19:16, 23 May 2018 editVioletriga (talk \| contribs)Extended confirmed users37,361 edits →top: strengthen that this is the key aspect← Previous edit		Revision as of 07:35, 24 May 2018 edit undoVioletriga (talk \| contribs)Extended confirmed users37,361 edits →Research: remove disputed content about ThielNext edit →
Line 6:		Line 6:
	The evidence suggesting the treatment could be beneficial was based on research done on rodents at ] in which blood transfused from young mice seemed to invigorate older mice.<ref name=Garraud2017/> The company, Alkahest, was spun out of Stanford based on that work, and as of 2017 was collaborating with European pharmaceutical company ] to create a ]-based experimental ] drug, which they propose to test on people with ].<ref name=Trends2017>{{cite journal\|last1=de Magalhães\|first1=JP\|last2=Stevens\|first2=M\|last3=Thornton\|first3=D\|title=The Business of Anti-Aging Science.\|journal=Trends in biotechnology\|date=November 2017\|volume=35\|issue=11\|pages=1062-1073\|doi=10.1016/j.tibtech.2017.07.004\|pmid=28778607}} {{open access}}</ref><ref>{{cite journal\|last1=Drew\|first1=L\|title=Neuroscience: The power of plasma.\|journal=Nature\|date=27 September 2017\|volume=549\|issue=7673\|pages=S26-S27\|doi=10.1038/549S26a\|pmid=28953857}}</ref>		The evidence suggesting the treatment could be beneficial was based on research done on rodents at ] in which blood transfused from young mice seemed to invigorate older mice.<ref name=Garraud2017/> The company, Alkahest, was spun out of Stanford based on that work, and as of 2017 was collaborating with European pharmaceutical company ] to create a ]-based experimental ] drug, which they propose to test on people with ].<ref name=Trends2017>{{cite journal\|last1=de Magalhães\|first1=JP\|last2=Stevens\|first2=M\|last3=Thornton\|first3=D\|title=The Business of Anti-Aging Science.\|journal=Trends in biotechnology\|date=November 2017\|volume=35\|issue=11\|pages=1062-1073\|doi=10.1016/j.tibtech.2017.07.004\|pmid=28778607}} {{open access}}</ref><ref>{{cite journal\|last1=Drew\|first1=L\|title=Neuroscience: The power of plasma.\|journal=Nature\|date=27 September 2017\|volume=549\|issue=7673\|pages=S26-S27\|doi=10.1038/549S26a\|pmid=28953857}}</ref>

	A startup company named Ambrosia has been selling "young blood transfusions" for $8,000 since 2017 under the guise of running a ], to see if such transfusions lead to changes in the blood of recipients.<ref name=sbm/><ref name=Trends2017/><ref>{{cite news\|last1=Haynes\|first1=Gavin\|title=Ambrosia: the startup harvesting the blood of the young\|url=https://www.theguardian.com/society/shortcuts/2017/aug/21/ambrosia-the-startup-harvesting-the-blood-of-the-young\|accessdate=23 May 2018\|work=The Guardian\|date=21 August 2017\|language=en}}</ref> Jeff Bercovici wrote in '']'' that "life-extension science is a popular obsession" in ] and that ] was a fad which started in the 2000s. Bercovici says that there are rumours of wealthy technology bosses "spending tens of thousands of dollars for the procedures and young-person-blood". Technology entrepreneur ] has an interest in young blood transfusion which he sees as a means to immortality; his company's chief medical officer and Thiel's personal health director contacted Ambrosia's founder Jesse Karmazin.<ref name="Inc">{{cite news\|url=https://www.inc.com/jeff-bercovici/peter-thiel-young-blood.html\|title=Peter Thiel Is Very, Very Interested In Young People's Blood\|surname=Bercovici\|first=Jeff\|work=Inc\|date=1 August 2016}}</ref>		A startup company named Ambrosia has been selling "young blood transfusions" for $8,000 since 2017 under the guise of running a ], to see if such transfusions lead to changes in the blood of recipients.<ref name=sbm/><ref name=Trends2017/><ref>{{cite news\|last1=Haynes\|first1=Gavin\|title=Ambrosia: the startup harvesting the blood of the young\|url=https://www.theguardian.com/society/shortcuts/2017/aug/21/ambrosia-the-startup-harvesting-the-blood-of-the-young\|accessdate=23 May 2018\|work=The Guardian\|date=21 August 2017\|language=en}}</ref> Jeff Bercovici wrote in '']'' that "life-extension science is a popular obsession" in ] and that ] was a fad which started in the 2000s. Bercovici says that there are rumours of wealthy technology bosses "spending tens of thousands of dollars for the procedures and young-person-blood".

	==References==		==References==

Revision as of 07:35, 24 May 2018

Young blood transfusion refers to transfusing blood specifically from a young person into an older person with the intention of creating a medicinal benefit. The scientific community currently views the practice as little more than snake oil.

Research

Evidence from two large studies in 2017 showed that transfusion of blood from younger donors to older people was either no different from, or led to worse outcomes than, blood from older donors. Research on blood transfusion outcomes has been complicated by the lack of careful characterization of the transfusion products that have been used in clinical trials; research had focused on how storage methods and duration might affect blood, but not on the differences among lots of blood themselves.

The evidence suggesting the treatment could be beneficial was based on research done on rodents at Stanford University in which blood transfused from young mice seemed to invigorate older mice. The company, Alkahest, was spun out of Stanford based on that work, and as of 2017 was collaborating with European pharmaceutical company Grifols to create a blood plasma-based experimental biologic drug, which they propose to test on people with Alzheimer's.

A startup company named Ambrosia has been selling "young blood transfusions" for $8,000 since 2017 under the guise of running a clinical trial, to see if such transfusions lead to changes in the blood of recipients. Jeff Bercovici wrote in Inc. that "life-extension science is a popular obsession" in Silicon Valley and that regenerative medicine was a fad which started in the 2000s. Bercovici says that there are rumours of wealthy technology bosses "spending tens of thousands of dollars for the procedures and young-person-blood".

References

^ Novella, Steven (3 August 2016). "Parabiosis – The Next Snakeoil". Science-Based Medicine.
^ Garraud, O (August 2017). "Younger blood from older donors: Admitting ignorance and seeking stronger data and clinical trials?". Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 56 (4): 635–636. doi:10.1016/j.transci.2017.07.002. PMID 28780993.
Ning, S; Heddle, NM; Acker, JP (January 2018). "Exploring donor and product factors and their impact on red cell post-transfusion outcomes". Transfusion medicine reviews. 32 (1): 28–35. doi:10.1016/j.tmrv.2017.07.006. PMID 28988603.
^ de Magalhães, JP; Stevens, M; Thornton, D (November 2017). "The Business of Anti-Aging Science". Trends in biotechnology. 35 (11): 1062–1073. doi:10.1016/j.tibtech.2017.07.004. PMID 28778607.
Drew, L (27 September 2017). "Neuroscience: The power of plasma". Nature. 549 (7673): S26 – S27. doi:10.1038/549S26a. PMID 28953857.
Haynes, Gavin (21 August 2017). "Ambrosia: the startup harvesting the blood of the young". The Guardian. Retrieved 23 May 2018.

Categories:

Revision as of 19:16, 23 May 2018 editVioletriga (talk \| contribs)Extended confirmed users37,361 edits →top: strengthen that this is the key aspect← Previous edit		Revision as of 07:35, 24 May 2018 edit undoVioletriga (talk \| contribs)Extended confirmed users37,361 edits →Research: remove disputed content about ThielNext edit →
Line 6:		Line 6:
	The evidence suggesting the treatment could be beneficial was based on research done on rodents at ] in which blood transfused from young mice seemed to invigorate older mice.<ref name=Garraud2017/> The company, Alkahest, was spun out of Stanford based on that work, and as of 2017 was collaborating with European pharmaceutical company ] to create a ]-based experimental ] drug, which they propose to test on people with ].<ref name=Trends2017>{{cite journal\|last1=de Magalhães\|first1=JP\|last2=Stevens\|first2=M\|last3=Thornton\|first3=D\|title=The Business of Anti-Aging Science.\|journal=Trends in biotechnology\|date=November 2017\|volume=35\|issue=11\|pages=1062-1073\|doi=10.1016/j.tibtech.2017.07.004\|pmid=28778607}} {{open access}}</ref><ref>{{cite journal\|last1=Drew\|first1=L\|title=Neuroscience: The power of plasma.\|journal=Nature\|date=27 September 2017\|volume=549\|issue=7673\|pages=S26-S27\|doi=10.1038/549S26a\|pmid=28953857}}</ref>		The evidence suggesting the treatment could be beneficial was based on research done on rodents at ] in which blood transfused from young mice seemed to invigorate older mice.<ref name=Garraud2017/> The company, Alkahest, was spun out of Stanford based on that work, and as of 2017 was collaborating with European pharmaceutical company ] to create a ]-based experimental ] drug, which they propose to test on people with ].<ref name=Trends2017>{{cite journal\|last1=de Magalhães\|first1=JP\|last2=Stevens\|first2=M\|last3=Thornton\|first3=D\|title=The Business of Anti-Aging Science.\|journal=Trends in biotechnology\|date=November 2017\|volume=35\|issue=11\|pages=1062-1073\|doi=10.1016/j.tibtech.2017.07.004\|pmid=28778607}} {{open access}}</ref><ref>{{cite journal\|last1=Drew\|first1=L\|title=Neuroscience: The power of plasma.\|journal=Nature\|date=27 September 2017\|volume=549\|issue=7673\|pages=S26-S27\|doi=10.1038/549S26a\|pmid=28953857}}</ref>

	A startup company named Ambrosia has been selling "young blood transfusions" for $8,000 since 2017 under the guise of running a ], to see if such transfusions lead to changes in the blood of recipients.<ref name=sbm/><ref name=Trends2017/><ref>{{cite news\|last1=Haynes\|first1=Gavin\|title=Ambrosia: the startup harvesting the blood of the young\|url=https://www.theguardian.com/society/shortcuts/2017/aug/21/ambrosia-the-startup-harvesting-the-blood-of-the-young\|accessdate=23 May 2018\|work=The Guardian\|date=21 August 2017\|language=en}}</ref> Jeff Bercovici wrote in '']'' that "life-extension science is a popular obsession" in ] and that ] was a fad which started in the 2000s. Bercovici says that there are rumours of wealthy technology bosses "spending tens of thousands of dollars for the procedures and young-person-blood". Technology entrepreneur ] has an interest in young blood transfusion which he sees as a means to immortality; his company's chief medical officer and Thiel's personal health director contacted Ambrosia's founder Jesse Karmazin.<ref name="Inc">{{cite news\|url=https://www.inc.com/jeff-bercovici/peter-thiel-young-blood.html\|title=Peter Thiel Is Very, Very Interested In Young People's Blood\|surname=Bercovici\|first=Jeff\|work=Inc\|date=1 August 2016}}</ref>		A startup company named Ambrosia has been selling "young blood transfusions" for $8,000 since 2017 under the guise of running a ], to see if such transfusions lead to changes in the blood of recipients.<ref name=sbm/><ref name=Trends2017/><ref>{{cite news\|last1=Haynes\|first1=Gavin\|title=Ambrosia: the startup harvesting the blood of the young\|url=https://www.theguardian.com/society/shortcuts/2017/aug/21/ambrosia-the-startup-harvesting-the-blood-of-the-young\|accessdate=23 May 2018\|work=The Guardian\|date=21 August 2017\|language=en}}</ref> Jeff Bercovici wrote in '']'' that "life-extension science is a popular obsession" in ] and that ] was a fad which started in the 2000s. Bercovici says that there are rumours of wealthy technology bosses "spending tens of thousands of dollars for the procedures and young-person-blood".

	==References==		==References==